524 results on '"Cross, N. C."'
Search Results
2. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia
3. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis
4. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis
5. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis
6. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event
7. Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling
8. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
9. Detection of leukemia-associated mutations in peripheral blood DNA of hematologically normal elderly individuals
10. An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis
11. Granulocyte colony-stimulating factor receptor T595I (T618I) mutation confers ligand independence and enhanced signaling
12. Mutations and prognosis in primary myelofibrosis
13. JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms
14. Standardized definitions of molecular response in chronic myeloid leukemia
15. A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia
16. IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis
17. Analysis of genomic breakpoints in p190 and p210 BCR–ABL indicate distinct mechanisms of formation
18. Harmonization of molecular monitoring of CML therapy in Europe
19. The molecular anatomy of the FIP1L1-PDGFRA fusion gene
20. Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions
21. Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1
22. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features
23. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders
24. The severity of FIP1L1–PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus
25. Chronic myeloid leukemia – some topical issues
26. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma
27. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells
28. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia
29. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma
30. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia
31. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma
32. The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1
33. Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript
34. Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies
35. Oncogenic protein tyrosine kinases: Oncogenic derivatives of platelet-derived growth factor receptors
36. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074
37. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase
38. Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients
39. Why do we see JAK2 exon 12 mutations in myeloproliferative neoplasms?
40. P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12
41. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation
42. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance
43. Possible transmission of Laugier–Hunziker syndrome by allogeneic peripheral blood stem cell transplantation
44. Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder
45. Constitutional genetic association with CALR mutations?
46. The evolution of the ribosomal DNA multigene family in tsetse fly species
47. No evidence for amplification of V617F JAK2 in myeloproliferative disorders
48. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease
49. Deep molecular response in chronic myeloid leukemia
50. The utility of in vitro testing for imatinib sensitivity in BCR-ABL negative myeloproliferative disorders
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.